Background: Simultaneous presentation of arteriovenous malformation (AVM) and glioblastoma multiforme (GBM) is rarely reported in the literature and needs to be differentiated from "angioglioma," a highly vascular glioma and other differential diagnosis such as hypervascular glioblastoma. Incorporating critical features of both, malignant glioma and AVM, such lesions lack a standard algorithm for diagnosis and therapy due to their rare incidence as well as their complex radiological and highly individualized clinical presentation. Case Description: We present a case of a 71-year-old female with newly developing motor deficits and radiographic findings of a heterogeneously contrast enhancing right-sided thalamic lesion with highly prominent vasculature. While computed tomography angiogram and cerebral digital subtraction angiography supported the diagnosis of AVM, contrast-enhancing magnetic resonance imaging (MRI) and MR-spectroscopy was suggestive of malignant glioma. A stereotactic biopsy revealed the diagnosis of a GBM (WHO IV) and the patient was treated accordingly.
BACKGROUND
Arteriovenous malformations (AVMs) associated with gliomas, in particular glioblastoma multiforme (GBM), are uncommon and remain infrequently reported in the literature. Due to the critical features of both entities, such AVM-associated malignant gliomas represent a challenging clinical entity in terms of diagnosis, therapeutic management, and risk assessment.
The pathological entity in these cases differs from other glioma-associated vascular lesions, e.g., the so-called "angiogliomas," which occur reportedly more frequently. Though potentially misleading during diagnostic evaluation, they are hypervascular low-grade lesions with a favorable prognosis. [8, 9, 14] Beyond this, are AVMs associated with GBM, which are characterized by distinct occurrence and location and have been described as rare coincidences elsewhere. [1, 4, 13] They may present simultaneously in distinct regions of the brain, [13] or occur sequentially in the same area, [13, 21] and single cases have been described as locally coinciding at diagnosis. [1, 4, 10] Third, distinct hypervascular glioblastomas have been described but are not classified as a separate pathological entity. However, all of the abovementioned cases remain a diagnostic and therapeutic challenge, considering their perplexing radiographic heterogeneity, and they need to be assessed in a comparative setting.
Here, we report a striking case of what was considered an AVM-associated glioma; we evaluate its clinical and radiological presentation and its subsequent management. By illustrating this case in the context of the existing literature, we seek to caution against diagnostic pitfalls and emphasize the need for an accurate histopathological diagnosis.
CASE PRESENTATION
A 71-year-old female presented to an outside hospital with a 1-month history of progressive lower left extremity weakness and a left foot drop with resulting difficult ambulating. Over the days prior to admission, she also developed difficulty in holding objects with her left hand. A cranial computed tomography (CT) showed an approximately 3.5 cm nodular right-sided thalamic lesion with heterogeneous enhancement, a central hypodensity, and mild midline shift [ Figure 1a ].
She was transferred to our tertiary care center for further evaluation. On admission, the patient showed persistent left hemiparesis. Based on the initial CT results, the differential diagnosis of the lesion included primary brain neoplasms, metastatic brain disease, lymphoma, and less likely abscess or inflammatory or demyelinating disease. Magnetic resonance imaging (MRI) with contrast was obtained, again demonstrating a poorly demarcated mass in the right thalamic area with plentiful irregular blood products. The lesion showed avid heterogeneous contrast enhancement with highly prominent vasculature consisting of multiple feeders and enlarged venous channels . This added to the differential diagnosis entities such as an AVM in combination with a malignant glioma, a hypervascular glioma, or atypical AVM, respectively.
To further assess the vasculature, a computed tomography angiography (CTA) was obtained. Here, the mass was characterized by numerous dense calcifications, as well as by intrinsic hemorrhage posteriorly [ Figure 2a ]. Other significant findings included marked dilatation of clustered vessels along the medial, posterior, and superior margins of this lesion [ Figure 2b and c]. No definite aneurysms were detected but could not be ruled out with certainty. The working diagnosis at this point included a large and partially thrombosed AVM, resulting in high flow enlarged draining veins and hemorrhage versus an aggressive glioma with neovascularization [ Figure 2c ]. A cerebral digital subtraction angiography (DSA) confirmed extensive hypervascularity and was interpreted as displaying AVM-typical morphology [ Figure 2d and e].
MR-perfusion was performed and showed high perfusion and markedly increased blood volume within the right thalamic lesion maintaining the concern for an AVM, whereas MR multivoxel spectroscopy indicated an increase in creatinine/choline peak ratio [ Figure 3 ], substantiating the working diagnosis of an underlying glioma.
Because the prognosis and treatment algorithms for an AVM and a malignant glioma differ substantially, a definite tissue-based diagnosis was required, however, it was only hesitantly considered given the high risk of procedural bleeding. A stereotactic biopsy was finally performed under general anesthesia using a CRW frame (Radionics Inc., Burlington, MA). Preoperative T1 gadolinium MR as well as CTA-images were fused to the intraoperative frame-based CT using the StereoCalc® and NeuroSight® Arc software (Radionics Inc., Burlington MA) allowing three-dimensional planning of coordinates. Meticulous attention was paid to the delineation of a suitable target area for the biopsy at the inferior margin of the hypervascular zone but avoiding any prominent vessels [ Figure 4a and b].
Multiple serial stereotactic biopsy specimen were ascertained for histopathological analysis using a set of unique microforceps with a cubic bite size of 1 mm 3 (Medical High Tech Inc., Emmendingen, Germany), as described by Warnke et al. [5] A total of 7 specimens were obtained in 1 mm steps (−3 mm to +3 mm from the target point) without hemorrhagic complications.
Intraoperative fresh frozen analysis showed malignant glioma. Final histopathological analysis revealed a densely cellular, astrocytic glial fibrillary acidic protein positive tumor with necrosis, thrombosed vessels, and scattered mitosis among irregular hyperchromatic nuclei. The proliferative index (MIB-1) was above 10%. Thus, final histopathologic diagnosis confirmed GBM with profound hypervascularity.
After an uneventful biopsy and discharge home, subsequent treatment consisted of involved field radiation and standard chemotherapy with Temozolomide, as per Stupp et al. [18] Given the poor prognosis of GBM at this age, no additional treatment was recommended for the vascular malformation possibly associated with this lesion since this was considered not to impact her remaining lifetime. As expected, our patient did well for several months before the tumor progressed at which point she decided not to pursue further treatment. She expired 6 months after her initial presentation.
DISCUSSION
Simultaneous presentation of vascular lesions and glioma are rare encounters, notably the coincidence of AVM and GBM. Formerly the term "angioglioma," originally used by Russell and Rubinstein to describe a composite intrinsic tumor of angiogenic and glial origin, included gliomas in combination with venous malformations, cavernous angioma or arteriovenous malformations. [17] This conceptually broad term has since undergone several revisions as some tumors have been shown to be hypervascular gliomas. [22] Angiogliomas encountered in a study by Lombardi et al. were represented in 12% of 51 supratentorial pilocytic astrocytomas, 5% of 104 cerebellar pilocytic astrocytomas, and 4% of 82 oligodendrogliomas. [14] These angiogliomas displayed focally dense vascularity as well as hyalinized dilated vasculature instead of distinct, regular veins or arteries. Accordingly, in our case, observations of non-ectatic venous structures were more suggestive of an AVM than the pattern seen in angioglioma. Unlike the latter, malignant gliomas may also appear densely vascularized because of growth factor-induced neovascularization. [14] Considering that our case turned out to be a malignant glioma displaying a vascularity resembling an AVM on radiographic studies, we favored the diagnosis of densely hypervascularized glioma and eliminated "angioglioma" from the differential diagnosis.
In a preeminent study addressing the association of AVM and glioma, 2277 patients with primary brain tumors and 222 patients with AVMs were reviewed. [13] Only 3 individuals of the cohort had both the pathologies, either simultaneously or sequentially (accounting for an exceptionally rare 0.1% association). In 2 of the 3 cases, the two pathological entities were present simultaneously, whereas in the 3 rd case, the tumor was presented 30 months after AVM resection. In two cases, the tumors were gliomas, and in the third, the tumor was a pituitary lesion. Two of the patients died due to progression of the malignant glioma, emphasizing the urgent treatment of the glioma in such AVM-glioma associations. [13] Contrasting with the low association of AVM and glioma found above, Ziyal et al. argued that such low incidence was likely an underestimate by the study because CT was the only imaging modality used. They, hence, concluded that the true incidence would be higher with modern imaging technologies such as MRI, emphasizing the importance of adequate diagnostic work up. [22] In the previous cases, imaging included CT or MRI in combination with a conventional angiogram. [1, 4, 22] Given the rare incidence of this scenario, no standard of diagnostic evaluation has been established yet. Thus, to our opinion, it should include MRI, metabolic imaging (e.g. MRS), and angiography (e.g. DSA or CTA).
In this case, the patient's management would have remained the same whether the diagnosis was hypervascularized GBM or AVM-associated GBM, however, treatment would have changed if it was an AVM only. Hence, obtaining histopathology was warranted to confirm the presence of the tumor and not to be misled by imaging suggestive of an AVM. However, distinguishing hypervascular GBM from AVM-associated GBM would have clinical implications only when considering complete surgical resection, which was impossible here. Instead we employed diligent three-dimensional stereotaxy, which allowed us to obtain the correct pathology without any procedural bleeding.
The reasoning for the pursuit of obtaining a tissue diagnosis is further illustrated by Gmeiner et al. [10] There, primary imaging and intraoperative impression of a lesion was indicative for an AVM, which was ultimately confirmed by tissue analysis showing "an accumulation of . vessels of various diameters displaying arterial and venous wall differentiation" as well as "some areas of old hemorrhage and reactive astrogliosis." However, their patient showed suspicious changes at the surgical site on MRI 2 months later. Therefore, histology sections were reinvestigated and additional sections were cut from the tissue blocks showing hallmarks of GBM in a very small area of one section. Although such scenarios are rare, it emphasizes the need for diligent histopathological workup of the entire specimen in cases presenting with unusual radiologic and clinical findings.
Given the low number of reported cases, one might question any specific pathoetiology of cases with concurrent AVM and glioma, which remains controversial. One theory brought up the notion of an AVM derived process in which neoplastic changes occur in the perivascular glial tissue. [13, 23] It has also been proposed that AVMs in such composite structures are induced by angiogenic factors, which lead to glial neoplastic proliferation of vascular stroma. [2] Highly vascular features of GBMs have been repeatedly demonstrated. With a 30-fold increase in tumor-associated vascular endothelial growth factor (VEGF) in patients with GBM, when compared to low-grade astrocytomas, VEGF has been established as an important factor in the vasculogenesis of glioblastomas. [15] Accordingly, GBMs became a prime target for treatment with novel antiangiogenic agents such as the VEGF antibody bevacizumab (Avastin).
Similarly, it has been shown that VEGF levels are increased in surgical specimens from brain AVMs. [19] In a related mouse model it was shown that VEGF antagonism reduced the number of neoplastic vessels. [19] Increasing evidence supports excessive VEGF expression as a fundamental part of brain AVM pathogenesis for both sporadic AVMs and AVMs in hereditary hemorrhagic telangiectasia (HHT), which endorses interruption of VEGF signaling as a therapeutic strategy for AVMs. Bevacizumab normalized cardiac output in HHT patients harboring liver AVMs, [7] and was effective in the treatment of severe epistaxis caused by hemorrhage from small mucosal AVMs (telangiectasias). [6] Based on this, a phase I study on the efficacy and safety of bevacizumab in brain AVM patients is about to start (NCT02314377). A common angiogenesis pathway may, thus, explain radiological similarities between these two pathologies. White et al. furthermore suggested that distinct genetic constellations might be at play in coincident cases. [20] Finally, it has been suggested that a common viral origin might explain the coexistence of AVMs and gliomas. [8] Although various reports have tried to address this specific brain pathology, individual constellations occur in the absence of any superior diagnostic or treatment scheme. Of the 13 reported cases, only 3 included treatment of the AVM as well as that of the glioma. [3, 11, 12] It is commonplace that any decision to treat should not only be guided by the dominant overall prognosis but also by the existing symptoms. [3, 11, 12, 16] In our case, the patient was only mildly symptomatic from the deep-seated lesion, which did not lend itself to resection. As recommended in previous studies, [16] it was determined by our multidisciplinary tumor board that the patient should be treated for her GBM because that would determine the patients' overall prognosis.
CONCLUSION
Coincidental presentation of a vascular lesion and malignant glioma is rare and represents a major challenge in diagnostic imaging and therapy since surgery in this setting carries a significant risk. However, a tissue-based diagnosis remains crucial for any targeted therapeutic approach. Treatment decisions addressing either one of these lesions are complicated because suitable options (e.g., radiosurgery and/or open resection) carry specific risks. This requires standardization of diagnostic and therapeutic approaches to allow for the most appropriate therapy. Whether there is any role for primary treatment with antiangiogenesis agents (e.g., bevacizumab) in this unique setting may be suggested by much anticipated results from ongoing clinical trials of such drugs in brain AVMs.
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